ProCE Banner Activity

Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams


Downloadable slides on the role of BTK inhibitors in the clinical management of patients with relapsed/refractory MCL.

Released: July 07, 2023



Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
Nashville, Tennessee

Kami Maddocks

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Beigene, Ltd. and Lilly.

BeiGene, Ltd.